Paraneoplastic syndromes can signal hidden cancers. Dr. Nirja Shah, MD, from UC San Diego Health, shared a rare case study.…
Browsing: Breast Cancer Treatment
At the ASBrS 2025 annual meeting, Dr. Lucy Maria De La Cruz, MD, from Georgetown University Hospital, shared vital insights…
What Are CDK4/6 Inhibitors? CDK4/6 inhibitors, such as abemaciclib and ribociclib, are changing breast cancer treatment for HR+/HER2- early-stage patients.…
A major study, NRG-NSABP B-51/RTOG 1304, published on June 4, 2025, in the New England Journal of Medicine, shows regional…
The I-SPY2 Trial is transforming breast cancer treatment, offering new insights into pre-surgery chemotherapy for invasive lobular breast cancer (ILC).…
Breast surgery is transforming patient care with innovative approaches. Oncoplastic breast surgery, for instance, merges art and science to improve…
The Camizestrant SERENA-6 trial shone at ASCO 2025, presented by Professor Nick Turner. This Phase 3 study targets ESR1-mutated, ER-positive,…
Date: February 8, 2025 The U.S. Food and Drug Administration (FDA) has recently granted approval for datopotamab deruxtecan (DLNK), a…
The FDA has recently approved Kisqali (ribociclib) in combination with a non-steroidal aromatase inhibitor (NSAI) for the treatment of early-stage…
Nadia Harbeck, MD, PhD, from the University of Münster, recently conducted a primary outcome analysis of the multicenter randomized PreCycle…
Breast Cancer Treatment: How is Biology’s Integration into the Clinic Transforming Healthcare? Hope Rugo By Hope Rugo, MD, FASCO, Professor,…
Overview of the ASCENT Trial and Trodelvy The ASCENT Trial (NCT02574455) is a Phase III study that compares Trodelvy (Sacituzumab…